• OXiGENE (OXGN) Phase 2 Results of CA4P for Neuroendocrine Tumors

       (0 reviews)

    Clinical and Regulatory
    Event Type: Phase 2 Results
    Timing: H2 2016
    Designation(s): Orphan Drug

    This event is set for a broad date range and therefore the exact timing is unknown. This adds a degree of risk.
    FDA special designations may increase the likelihood of success and decrease the time to approval.
    Learn More

    Disease and Treatment
    Disease: Oncology
    Indication: Neuroendocrine Tumors
    Lead Indication?: Yes
    Treatment Name: CA4P (Fostrebutalin)

    Likelihood of event success varies depending on disease, treatment and lead indication classification.
    Learn More

    Company Information
    Co. Name: OXiGENE
    Stock Symbol: OXGN
    Shares Traded: NASDAQ

    The OTC BB and OTC Markets have less stringent reporting and financial requirements than the NASDAQ and NYSE. This may increase the level of risk for investors. Smaller size may have an influence on likelihood of success.
    Learn More

    Event Status
    Event Outcome: Ongoing
    Event Discussion: Forums
    Event Announcement(s): http://investor.mateon.com/releasedetail.cfm?releaseid=937175
    Partnership: No

    Partnerships help smaller biotech companies finance the long approval process. Partnership also provides validation the clinical program may be a worthy investment.
    Learn More

    Detailed Event Description from Company Announcement


    "The encouraging interim results seen in this Phase 2 study add to the body of evidence showing that CA4P has a positive effect in the treatment of solid tumors," said William D. Schwieterman , MD,  OXiGENE's  President and CEO. "We look forward to full results from this trial anticipated in the second half of 2016, as we simultaneously move to advance CA4P in later-stage trials in our core programs for ovarian cancer and glioblastoma multiforme, which will evaluate CA4P in combination with complementary, approved anti-angiogenic agents."


      Report Event

    User Feedback

    There are no reviews to display.